Dr. Kevin Hodgetts is the Director of LDDN and Head of Medicinal Chemistry. Kevin has a broad background in organic and medicinal chemistry, with experience in both industrial and academic drug discovery. He spent more than 15 years of experience working on treatments for diseases of the central nervous system and was closely involved with two molecules that entered Phase II clinical trials.
Kevin joined the LDDN in September 2012, to work with the academic community to design new and innovative strategies for drug discovery for neurodegenerative diseases (e.g. Alzheimer’s Disease, Amyotrophic lateral sclerosis and Spinal Muscular Atrophy). He is also an Assistant Professor of Neurology at Brigham and Women's Hospital and Harvard Medical School.